|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry in primary breast tumor tissue array showed tumor dependent expression of EZH2.
|
30760814 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we explored whether (i) EZH2 is overexpressed in human <i>BRCA1</i>-deficient breast tumors and might predict sensitivity to DSB-inducing drugs; (ii) EZH2 inhibition potentiates cisplatin efficacy in <i>Brca1</i>-deficient murine mammary tumors.
|
31036541 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry in primary breast tumors of different grades showed a correlated expression of estrogen-related receptors and EZH2.
|
29940916 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, inhibition of Ezh2 in a murine Brca2<sup>-/-</sup> breast tumour model is associated with acquired PARPi resistance.
|
29035360 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Conversely, transgenic EZH2 overexpression accelerates mammary tumor initiation and increases NOTCH1 activation in mouse mammary tumor virus-neu mice.
|
24516139 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
EZH2 and paxillin expression and DNA ploidy were evaluated in imprint smear samples obtained from 105 breast tumors after surgical removal.
|
24344012 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have analyzed the abundance of EZH2 and H3K27me3 using immunohistochemistry in two large and well-characterized breast tumor data sets encompassing more than 400 tumors.
|
22766277 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival.
|
21892211 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, critical mechanism linking increased EZH2 expression to BTIC (breast tumor initiating cell) regulation and cancer progression remains unclear.
|
21215703 |
2011 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
In a recent report, EZH2-mediated epigenetic repression of DNA damage repair in breast tumor initiating cells (BTICs) was identified as a mechanism that could promote expansion of BTICs, and may contribute to cancer progression.
|
21672285 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MiR-214 expression was inversely correlated with Ezh2 mRNA and protein levels in breast cancer cell lines and at least one copy of the miR-214 alleles was found to be deleted in 24% (6/25) of primary breast tumors.
|
21828058 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
|
21903722 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Consistent with the overexpression of EZH2 in a variety of human cancers including breast cancer, CDKN1C in these cancers is downregulated, and breast tumors expressing low levels of CDKN1C are associated with a poor prognosis.
|
19340297 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1.
|
18269588 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.
|
17018586 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
|
16855786 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
|
14965441 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
|
14500907 |
2003 |